Phyllis Amivi Ehlan
Datos Biográficos
| ID | 10241803 |
|---|---|
| NOMBRE | Phyllis Amivi Ehlan |
| NOMBRES | Phyllis Amivi |
| APELLIDO | Ehlan |
| FIRMA | EHLAN P A |
| AFILIACIONES | Department of STD, AIDS and Viral Hepatitis |
| VERIFICADO | No |
| TOTAL DE OBRAS | 1 |
| TOTAL DE CITAS | 0 |
| TOTAL COMO AUTOR | 1 |
| TOTAL COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2025 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2025 |
| ÍNDICE H | 0 |
Prevalence of primary HIV-1 drug resistance among antiretroviral-naïve individuals in Togo in 2023
Monitoring pre-treatment drug resistance is a priority to assess the emergence of HIV resistance to antiretrovirals, especially in countries where the transition from dolutegravir-based regimens is already effective on a large scale. The aim of this study was to estimate the prevalence of resistance mutations to different classes of antiretrovirals (ARVs) in HIV-1-naïve persons in Togo in 2023. A cross-sectional study was conducted in 30 HIV care…
Sin obras prominentes en esta página.
Prevalence of primary HIV-1 drug resistance among antiretroviral-naïve individuals in Togo in 2023
Monitoring pre-treatment drug resistance is a priority to assess the emergence of HIV resistance to antiretrovirals, especially in countries where the transition from dolutegravir-based regimens is already effective on a large scale. The aim of this study was to estimate the prevalence of resistance mutations to different classes of antiretrovirals (ARVs) in HIV-1-naïve persons in Togo in 2023. A cross-sectional study was conducted in 30 HIV care…
Biological Research and Disease Studies (1 obras) · Dolutegravir (1 obras) · Drug resistance (1 obras) · Elvitegravir (1 obras) · HIV drug resistance (1 obras) · HIV Research and Treatment (1 obras) · HIV/AIDS drug development and treatment (1 obras) · Integrase (1 obras) · Integrase inhibitor (1 obras) · Interquartile range (1 obras)